Search Results
Dec 16, 2025, 08:30 ET Allink Biotherapeutics Completes $47M Extension Rounds of Series A to Accelerate Clinical Programs and Novel Platforms Development
supportersProceeds to advance two differentiated and highly competitive ADC programs in global Phase I trialsThe financing will support continued development of ADC and multi-specific antibody platforms aimed at addressing critical limitations of existing biologic
More news about: Allink Biotherapeutics
Dec 16, 2025, 02:30 ET Allink Biotherapeutics Completes $47M Extension Rounds of Series A to Accelerate Clinical Programs and Novel Platforms Development
supportersProceeds to advance two differentiated and highly competitive ADC programs in global Phase I trialsThe financing will support continued development of ADC and multi-specific antibody platforms aimed at addressing critical limitations of existing biologic
More news about: Allink Biotherapeutics
Dec 16, 2025, 02:30 ET Allink Biotherapeutics schließt eine Finanzierungsrunde der Serie A in Höhe von 47 Millionen US-Dollar ab, um klinische Programme und die Entwicklung neuartiger Plattformen voranzutreiben
UnterstützernErlöse zur Förderung von zwei differenzierten und äußerst wettbewerbsfähigen ADC-Programmen in globalen Phase-I-StudienDie Finanzierung wird die weitere Entwicklung von ADC- und multispezifischen Antikörperplattformen unterstützen, die darauf abzielen, kritische Einschränkungen
More news about: Allink Biotherapeutics
Dec 16, 2025, 02:30 ET Allink Biotherapeutics conclut des tours de table supplémentaires de 47 millions de dollars de la série A pour accélérer les programmes cliniques et le développement de nouvelles plates-formes
de deux programmes de conjugués anticorps-médicaments (ADC) différenciés et hautement compétitifs dans le cadre d'essais de phase I à l'échelle mondialeLe financement permettra de poursuivre le développement de plateformes ADC et d'anticorps multispécifiques afin de remédier aux
More news about: Allink Biotherapeutics
Dec 15, 2025, 19:30 ET 安領科生物完成近5000萬美元A輪追加融資，加速ADC項目全球臨床及創新技術平台開發
是對公司 ADC 技術平台實力的有力驗證，產品的差異化價值也日益凸顯。我們非常期待近期的臨床數據讀出，也看好公司研發平台能持續湧現出更多源頭創新成果。」「安領科生物團隊兼具國際化的戰略視野與極致的執行力，在競爭激烈的 ADC 賽道中跑出了稀缺的『安領科加速度』。」美團龍珠醫療負責人、董事總經理郭學婧表示，「我們高度認可安領科技術平台的延展潛力，期待與團隊攜手，共同推動更多中國源頭創新在世界各地落地，早日惠及全球患者。」關於安領科生物安領科生物成立於2023年，是一家聚焦腫瘤及免疫領域的臨床階段生物技術公司，致力於差異化 ADC 及多特異性抗體的研發創新。基於創新平台技術與卓越研發效率的雙重驅動，公司已迅速將兩款
More news about: Allink Biotherapeutics
Dec 15, 2025, 14:58 ET Roche receives FDA approval for first diagnostic tests to identify HER2-positive metastatic breast cancer patients eligible for ENHERTU
who may be eligible for treatment with ENHERTU® (trastuzumab deruxtecan), a specifically engineered HER2-directed antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed and commercialised by Daiichi Sankyo and AstraZeneca.
More news about: Roche
Dec 15, 2025, 05:00 ET Minghui Pharmaceutical Announces FDA clearance of IND to Initiate Global Phase Ⅲ Trials of MHB018A, a Subcutaneous Single-Domain IGF-1R Antibody, in Thyroid Eye Disease
biotechnology innovator with two complementary growth engines: a robust clinical oncology portfolio built on its proprietary antibody-drug conjugate (ADC) platform and a novel PD-1/VEGF bispecific antibody (bsAb), and late-stage autoimmune assets advancing toward commercialization. The Company's pipeline
More news about: Minghui Pharmaceutical
Dec 12, 2025, 08:45 ET Actinium Pharmaceuticals Presents New Preclinical Data Demonstrating Potent Anti-Tumor Activity of ATNM-400 Across Multiple Breast Cancer Subtypes Including Hormone Receptor-Positive, Triple-Negative, and Tamoxifen- and HER2 Therapy-Resistant Breast Cancer Models at SABCS 2025
(TAGRISSO®, AstraZeneca) an EGFR tyrosine kinase inhibitor (TKI), second-line Dato-DXd (Datroway®, AstraZeneca/Daiichi Sankyo) a Trop-2 ADC, and third-line amivantamab (Rybrevant®, Johnson & Johnson) an EGFR-cMET bispecific had sales of approximately $7 billion in 2024 with
More news about: Actinium Pharmaceuticals, Inc.
Dec 12, 2025, 07:00 ET Marengo to Present Initial Results from Invikafusp Alfa and TRODELVY® Combination Study, STARt-002, at the 2025 San Antonio Breast Cancer Symposium
Massachusetts General Hospital Cancer Center. "The combination of Invika with TRODELVY® is scientifically compelling — pairing targeted T cell activation with ADC-mediated tumor killing. Seeing consistent Vβ6/10 expansion alongside early tumor responses reinforces the potential of this regimen to meaningfully benefit
More news about: Marengo Therapeutics
Dec 11, 2025, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
YORK, Dec. 11, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA ("ADC Therapeutics" or the "Company") (NYSE: ADCT). Such investors are advised to contact Danielle Peyton at
More news about: Pomerantz LLP
Dec 11, 2025, 07:30 ET TuHURA Biosciences Provides Corporate Update Following Recent Financing
basket trial; data on inhibiting DOR on MDSCs, TAMs and T regs at a scientific conference in 2Q; and proof-of-concept data in animal models for our lead ADC at a scientific conference in Q4 2026.""In an encouraging development in our VISTA inhibiting antibody (TBS-2025) clinical program, at a mini
More news about: TuHURA Biosciences, Inc.
Dec 11, 2025, 07:00 ET Biohaven Presents Clinical Safety and Efficacy Data for BHV-1510, a Next-Generation Trop2 Antibody Drug Conjugate in Combination with Cemiplimab at the 2025 European Society for Medical Oncology (ESMO) Immuno-Oncology Congress
treatment. The pharmacokinetic profile for BHV-1510 was favorable, the unconjugated payload concentration was low with a payload-to-ADC molar ratio < 1%, indicating that ADC was highly stable in the circulation.Nushmia Khokhar, M.D., Chief Medical Officer of Oncology at Biohaven, commented, "Continued
More news about: Biohaven Ltd.
Dec 10, 2025, 16:01 ET Nuvalent Appoints Ron Squarer to Board of Directors
delivering a new generation of precisely targeted therapies to patients with cancer."Mr. Squarer currently serves as the Board Chair of ADC Therapeutics and as a Board member at Travere Therapeutics. Mr. Squarer earned an M.B.A. from the Kellogg School of Management, Northwestern University,
More news about: Nuvalent, Inc.
Dec 08, 2025, 08:34 ET GlycoNex Signs CDMO Service Agreement with Change Cure to Advance HMGB1-Targeted Antibody Program
and high-quality biosimilars to advance next-generation biologic therapies. The company's lead program, GNX1021, is a first-in class glycan-directed ADC targeting the branched Lewis B/Y (bLeB/Y) antigen, which has demonstrated potent tumor-suppressive activity in preclinical studies and is expected to
More news about: GlycoNex, Inc.
Dec 08, 2025, 07:50 ET TuHURA Biosciences Presents Data Demonstrating the Delta Opioid Receptor (DOR) as a New Target in Overcoming Acquired Resistance to Immune Checkpoint Inhibitors at the 57th ASH Annual Meeting and Exposition
and is in position to advance our first-in-class immune modulating bi-functional, bi-specific antibody drug conjugates (ADCs). We anticipate our lead ADC candidate to consist of a DOR inhibitor conjugated to our VISTA inhibiting antibody. TuHURA's updates at this ASH meeting demonstrate that elucidating
More news about: TuHURA Biosciences, Inc.
Dec 07, 2025, 21:00 ET Median PFS Trending Beyond One Year: Leads Biolabs' LBL-034 Showcases Breakthrough Clinical Data in Oral Presentation at the 2025 ASH Annual Meeting
proprietary technology platforms, including LeadsBody platform (a CD3 T-cell engager platform), X-body platform (a 4-1BB engager platform), TOPiKinectics (ADC platform), which serve as the cornerstone for our continued innovation and have been validated by the clinical outcomes of our bispecific antibody portfolios.We
More news about: Leads Biolabs
Dec 07, 2025, 01:09 ET 喜訊！科倫博泰佳泰萊®、達泰萊®、科泰萊®成功納入2025國家基本醫保目錄
其第二項新增適應症獲批上市，用於治療經表皮生長因數受體酪氨酸激酶抑制劑（EGFR-TKI）和含鉑化療治療後進展的EGFR突變陽性的局部晚期或轉移性非鱗狀非小細胞肺癌（NSCLC），這也讓其成為全球首個在肺癌適應症上獲批的TROP2 ADC。此次國家基本醫保目錄公佈，蘆康沙妥珠單抗的兩項適應症均被成功納入。 蘆康沙妥珠單抗單藥治療二線及以上晚期TNBC的關鍵III期臨床研究資料顯示：（１）無進展生存期（PFS）方面，截至2023年6月21日，蘆康沙妥珠單抗的中位PFS為5.7個月，相比化療顯著延長，疾病進展或死亡風險顯著降低69%；
More news about: 科伦博泰
Dec 04, 2025, 18:38 ET Innovent Biologics Announces Closing of Global Strategic Partnership with Takeda for Next-Generation IO and ADC Therapies
next-generation immuno-oncology (IO) and antibody-drug conjugate (ADC) therapies, including the global partnership on IBI363 (PD-1/IL-2α-bias) and IBI343 (CLDN18.2 ADC), and an option for an early-stage program IBI3001 (EGFR/B7H3 ADC). Dr. Hui Zhou, Chief R&D Officer for Oncology Pipeline
More news about: Innovent Biologics
Dec 04, 2025, 08:30 ET Caris Life Sciences to Showcase 19 Studies at the 2025 San Antonio Breast Cancer Symposium
(RW) Clinical-Multiomics Data. #PD3-02Poster Spotlight 3. December 10, 2025. 7:33-7:36 AM CSTOvercoming ADC Resistance: Payload Diversification as a Strategy for Sequential Therapy. #PD3-11Poster Spotlight 3. December 10, 2025.
More news about: Caris Life Sciences
Dec 04, 2025, 08:00 ET Network Security Market to Exceed $26 B in 2025 as SSE and WAF Lead Cloud-Delivered Expansion, According to Dell'Oro Group
Network Security Quarterly Report includes manufacturers' revenue covering the ADC, Firewall, SSE, traditional SWG appliances, and WAF product segments. Moreover, SSEs are further broken down across four primary functions: CASB, FWaaS,
More news about: Dell'Oro Group
Dec 03, 2025, 07:30 ET ADC Therapeutics Announces Updated Data from LOTIS-7 Phase 1b Clinical Trial of ZYNLONTA® in Combination with Bispecific Antibody Supporting Potential Best-in-Class Regimen in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma
treatment for patients through our focused portfolio with ZYNLONTA (loncastuximab tesirine-lpyl) and an early-stage PSMA-targeting ADC.ADC Therapeutics' CD19-directed ADC ZYNLONTA received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed
More news about: ADC Therapeutics SA
Dec 02, 2025, 16:05 ET ADC Therapeutics to Provide Update on LOTIS-7 Clinical Trial
treatment for patients through our focused portfolio with ZYNLONTA (loncastuximab tesirine-lpyl) and an early stage PSMA-targeting ADC.ADC Therapeutics' CD19-directed ADC ZYNLONTA received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed
More news about: ADC Therapeutics SA
Dec 02, 2025, 06:40 ET Prescription Drugs Market Poised for Substantial Growth, Driven by Novel Therapies and Evolving Regulatory Landscape: Reaching US$2.15 Trillion by 2032
agreements. Notably, regulatory news included the US FDA granting Breakthrough Therapy Designation for several novel Antibody-Drug Conjugate (ADC) candidates targeting lung and breast cancers in September 2025, a quantitative marker of accelerated development. The strategic acquisition focus remains
More news about: DataM Intelligence 4 Market Research LLP
Dec 02, 2025, 04:12 ET Yatsen Group、「Beauty Innovation Insight」白書を発表
さらに2025年8月、Yatsen Groupは第35回IFSCC世界大会において本白書の英語版を発表しました。中国の化粧品R&D成果が、初めて包括的かつ国際的な査読を経た形で紹介されました。過去4年間でYatsen GroupはIFSCC、EADV、ADC、WCDといった主要な皮膚科学・化粧品学会に参加し、中国の科学的発信力を国際舞台で高めています。「ラボから市場へ」―科学を美へと変える力本白書では、Yatsen Groupが研究室で得た発見をどのように消費者価値へ転化しているかを紹介しています。グループの主力ブランド「Perfect
More news about: Yatsen Holding Limited
Dec 02, 2025, 04:00 ET Antengene Announces IND Approval in China for Phase Ib/II Study of ATG-022 (CLDN18.2 ADC) in Combination with KEYTRUDA® (Pembrolizumab) ± Chemotherapy
has approved the investigational new drug (IND) application for the Phase Ib/II CLINCH-2 study evaluating ATG-022 (CLDN18.2 antibody-drug conjugate [ADC]) in combination with MSD's (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), as well as ATG-022 in combination
More news about: Antengene Corporation Limited